Corbus announced today that the U.S. FDA has granted Fast Track designation to CRB-701 for the treatment of relapsed or refractory metastatic #cervicalcancer. CRB-701 (SYS6002) is a next-generation #AntibodyDrugConjugate (ADC) targeting Nectin-4 that contains a site-specific, cleavable linker and a precise drug antibody ratio of 2 using MMAE as the payload. For more information, visit: https://bit.ly/3ZiAz0f | Corbus Pharma

Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will present a corporate overview and attend investor meetings at the 36th Annual Oppenheimer Healthcare Life Sciences Conference, to be held virtually February 25-26, 2026 For details: https://bit.ly/4rKkfC1 | Corbus Pharma

Reminder: Yuval Cohen, Ph.D., CEO of Corbus, will present a corporate overview at the 44th Annual J.P. Morgan Healthcare Conference tomorrow at 8:15 a.m. PST/11:15am EST. For webcast details: https://bit.ly/4js7Obg #JPM26 #JPM2026 | Corbus Pharma